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who underwent allogenic SCT in two tertiary institutions in Singa-
pore between 2006 and 2010. The studied outcomes included CMV
reactivation, CMV disease, and 100-day mortality.
Results: 179 CMV-seropositive patients (median age 43) who un-
derwent myeloablative (N 5 78) and nonmyeloablative (N 5 101),
related (N 5 122) and unrelated (N 5 57) donor allogenic SCT
were identified. Among them, 145 (81%) had a CMV-seropositive
donor, and 34 (19%) had a CMV-seronegative donor. Median fol-
low-up time was 8.2 months. There were no significant differences
in the studied outcomes. CMV reactivation occurred in 93 (64%) pa-
tients in the CMV-seropositive donor group, and 23 (68 %) patients
in the CMV-negative donor group. CMV disease occurred in 4 (3%)
patients in the CMV-seropositive donor group and 2 (6%) in the
CMV-seronegative donor group. The 100-day mortality was 11%
in both the CMV-seronegative and CMV-seropositive donor group.
There was no statistically significant difference in 3 year disease free
survival between the two groups. A secondary aim of establishing risk
factors for CMV reactivation was performed. In multivariate analy-
sis, the use of thymoglobuline prophylaxis was observed to be the
only significant predictors for CMV reactivation. Patients receiving
thymoglobuline prophylaxis were observed to be 3.6 times more
likely to experience CMV reactivation, as compared to those who
did not receive it.
Conclusions:Our study shows that donor CMV serologic status did
not significantly affect the incidence of CMV reactivation, CMVdis-
ease, 100- day mortality, and disease free survival in CMV-seropos-
itive patients undergoing allogenic SCT. The use of thymoglobuline
prophylaxis, however, remains the most important risk factors for
CMV reactivation.351
INVASIVE FUNGAL INFECTIONS IN PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANT PATIENTS, A RETROSPECTIVE ANALYSIS
Rosenthal, J.1, Ito, J.2, Tegtmeier, B.2,Wolfson, J.1, April, S.1, Cheng, J.3,
Pawlowska, A.1 1City of Hope, Duarte, CA; 2City of Hope, Duarte, CA;
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Background: Invasive fungal infections (IFI) remain a major cause
of morbidity and mortality in patients (pts) undergoing HCT. The
epidemiology of IFI has changed, with a higher proportion of mould
infections reported compared to earlier reports (Marr et al. Clin In-
fect Dis. 2002). The incidence of IFI in children undergoing HCT
has been reported at a range of 1.6-25%. The changes in epidemiol-
ogy of IFI are attributed to multiple factors, including corticosteroid
treatment, graft-versus-host disease (GVHD), increase in trans-
plants from alternative donors, and emergence of resistance with
use of azoles for IFI prevention. We report a low incidence of IFI
in pediatric patients treated in an arid region, using low-dose ampho-
tericin prophylaxis.
Methods:Medical records of 49 of 501 pediatric pts who had under-
gone 550 HCT procedures at our center between January 1997 and
August 2010 have been reviewed. Categorical tables were analyzed
using Pearson’s chi-square test and the Cochran-Mantel-Haenszel
test. Tabular and graphical descriptive survival analyses were per-
formed using cumulative incidence methods accounting for compet-
ing risks.
Results: Probable or proven IFI were diagnosed in 49 pts; 44 were
diagnosed within 2 years of HCT and were considered to be related
to treatment. The median age was 12.8 years (range 1-19.6 years).
Amphotericin based prophylaxis was used in 39 pts (87%) and other
agents in 5 pts (13%). Yeast and mould infections were diagnosed in
17 (2.7%) and 29 (5.2%) patients respectively. Two patients had
both yeast and mould infections. Yeast infection was bi-phasic, the
first peak (n 5 11) occurring at a median of 56 days (2-360) and
the second (n 5 6) at 400 days (365-478), post HCT, respectively.
The median day for mould infection was day +142 (10-726). HCT
modality, GVHD, steroid use, co-infection with viral or bacterial in-
fection and previous HCT were associated with IFI. The immediate
outcome of the event was resolution (n5 16, 37%), death from fun-
gal infection (n 5 12, 28%) death of disease progression (n 5 8,19%), GVHD (n 5 4, 8%) and death from other transplant related
complications (n 5 4, 8%),
Conclusion: The risk of IFI reported here appears to be lower than
historical data. This may be related to the vast use of low-dose am-
photericin formulations for prophylaxis, the arid climate, or a combi-
nation of both. A prospective study is needed to further elucidate the
role of low-dose amphotericin in prevention of IFI in HCT pts.352
INCIDENCE OF HYPERGLYCEMIA IN ACUTE ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT
Schlatter, M., Gregory, T.K., Panter, E., Maris, M.B., McSweeney, P.
Colorado Blood Cancer Institute, Denver, CO
Introduction: Medical literature has established adverse clinical
outcomeswith hyperglycemia and adverse events in the inpatient set-
ting. There is a paucity of literature documenting the incidence and
subsequent effects of hyperglycemia in HSCT patients. The data in
other populations shows decreased rates of infection, morbidity and
mortality with improved glycemic control. This suggests that im-
proved glycemic control in the HSCT setting could reduce rates
of infection, GvHD, and TRM. The goal of this study is to describe
the incidence of hyperglycemia in the allo HSCT population.
Patients and Methods: A chart review was conducted on a total of
167 HCST patients up to day +100. Thirty normoglycemic, auto
HSCT recipients served as controls. The remaining 137 were allo
HSCT recipients. The primary endpoint was the incidence of hyper-
glycemia defined as one random blood glucose (BG) . 180 mg/dL.
Severe hyperglycemia was defined as BG . 250 mg/dL. Secondary
endpoints included administration of steroids, insulin, and death.
Results were analyzed utilizing Pearson’s chi squared test.
Results: Sixty patients had at least one BG from 180-250mg/dL and
68 had a BG . 250 mg/dL. The overall incidence of hyperglycemia
(. 180 mg/dL) was 76% in the study group compared to zero inci-
dence in the control group (p0.007). The majority of patients with
hyperglycemia received insulin therapy (95%). Probability of day
+100 survival was 72% if BG . 250 mg/dL, 84% for level of 180-
250 mg/dL, and 96% with levels\ 180 mg/dL. The survival rate
in the allo study group for BG\ 180 mg/dL was 96% compared
to 77% for a BG . 180 (p0.008).
Conclusions:While there is a clear increased incidence of hypergly-
cemia in the allo HSCT population, it remains unclear if this is caus-
ally related to adverse outcomes. Many factors impact survival
probability and the relationship of aggressive glucose control and
improved outcomes have yet to be examined. Further study of hyper-
glycemia, confounding variables, and aggressive insulin therapy in
a randomized, prospective manner is needed.353
INHALED AEROSOLIZED RIBAVIRIN TREATMENT IN RAPID ANTIGEN
TEST NEGATIVE AND MULTIPLEX PCR POSITIVE RESPIRATORY SYNCY-
TIAL VIRAL PNEUMONIA AFTER STEM CELL TRANSPLANTATION: A SIN-
GLE CENTER EXPERIENCE OVER TWO WINTER SEASONS
Ganguly, S.1, Ganguly, N.2, Carson, S.3, Aljitawi, O.1, Abhyankar, S.1,
McGuirk, J.P.1 1University of Kansas Medical Center, Kansas City, KS;
2University of Kansas Medical Center, Kansas City, KS; 3University of
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Respiratory Syncytial Virus (RSV) pneumonia leading to respira-
tory failure can be a significant cause of acute morbidity and mortal-
ity in the immuno-compromised host, with mortality rates of 70 to
100 percent being described in bone marrow transplant recipients.
High level of suspicion, availability ofmultiplex polymerase chain re-
action (PCR) technique for early detection, and immediate interven-
tion by inhaled Ribavirin may lead to improved outcome.
As a policy of our program, nasal wash samples from the transplant
recipients with respiratory symptoms are routinely sent for both
rapid antigen detection tests as well as for multiplex respiratory viral
panel PCR. We identified a total of 6 patients with RSV pneumonia
S282 Poster Session Iproven by CT scan of chest over two winter seasons (two in 2009 and
four in 2010). Median onset of RSV pneumonia in this cohort was 18
months from the date of transplantation (range: 3 months – 8 years).
Patients were diagnosed by positive PCR assay (Three with RSV-A
and 3 with RSV-B). The rapid antigen detection test (Binaxnow, In-
verness Medical) was negative for RSV in all 6 patients. All 6 patients
were sent home from the clinic based on the negative antigen test and
were later admitted to the hospital when the PCR result was available
(range 1-3 days). Patients were treated with aerosolized Ribavirin at
a dose of 2 g. every 8 hours for 3-5 days. No complication was ob-
served other than treatment related bronchospasm that was easily
managed by concomitant inhaled bronchodilators. Most common
complaint was a feeling of claustrophobia associated with the tent
used at the time of treatment delivery. With a median follow up of
4 months (range; 1- 14 months), all patients had shown complete
clinical recovery as well as radiological improvement. There was
no relation between immune-reconstitution to the onset or severity
of the infection.
In conclusion, we recommend universal use of multiplex PCR
based technique for respiratory viral pathogens in stem cell trans-
plant recipients with respiratory symptoms over antigen based detec-
tion test. Early detection and prompt institution of therapy with
inhaled ribavirin may be responsible for 0% mortality in our cohort
compared to published literature.354
SEPSIS MANAGEMENT – HOW SHOULD THE SEPSIS BUNDLE BE UTI-
LIZED IN THE BLOOD AND MARROW TRANSPLANT UNIT?
Rice, J.M. The Ohio State University James Cancer Hospital, Columbus,
OH
In January of 2009, The Ohio State University Medical Center
(OSU) implemented the sepsis bundle guideline. This guideline in-
tended to provide a standard for early recognition of sepsis, provide
initial resuscitative measures, and to provide a pathway for initial
management as well as maintenance of sepsis treatment. All patients
that met initial criteria would have the sepsis bundle implemented.
With initiation of the sepsis bundle on all patients who met crite-
ria, the Blood and Marrow Transplant (BMT) Program at OSU
James Cancer Hospital reviewed their current practice for manage-
ment of these patients. Current practice is to utilize a febrile neutro-
penic pathway rather than the sepsis bundle. As it became apparent
that the sepsis bundle and the febrile neutropenic pathway were
different, a retrospective review of 30 patients was performed from
September 7, 2009 through February 10, 2010. The goal of the
review was to identify patient outcomes in those patients that met
criteria for the sepsis bundle yet were managed via the neutropenic
pathway.
Of the 30 patients reviewed, all met minimum criteria for initia-
tion of the sepsis bundle. All patients were managed via the neutro-
penic pathway rather than the sepsis bundle. In the end, 28 patients
were alive at 30 days with no complications associated with infection.
One patient was discharged to hospice related to graft failure and
multiorgan failure. The other patient developed complications
with respiratory compromise, ARDS, and multiorgan failure and
died as a result associated with ARDS.
This review suggests that BMT patients do not meet normal cri-
teria for implementation of the sepsis bundle. Ongoing discussions
continue to attempt to define specific criteria for implementation
of the sepsis bundle in the bone marrow transplant population.355
RETROSPECTIVE ANALYSIS OF THE EFFICACY OF ANTIEMETIC PROPHY-
LAXIS IN DIFFERENT PREPARATIVE REGIMENS FOR AUTOLOGOUS AND
ALLOGENEIC BONE MARROW TRANSPLANTATION
Duquette, D.1,3,4, Adam, J.-P.1, Goulet, D.1,3,4, Delage, R.2,5 1Centre
Hospitalier Affilie Universitaire de Quebec - Ho^pital Enfant-Jesus,
Quebec, QC, Canada; 2Centre Hospitalier Affilie Universitaire de Quebec
- Ho^pital Enfant-Jesus, Quebec, QC, Canada; 3Universite Laval, Quebec,QC, Canada; 4Centre Hospitalier Affilie Universitaire de Quebec, Quebec,
QC, Canada; 5Universite Laval, Quebec, QC, Canada
Chemotherapy-induced nausea and vomiting (CINV) is of partic-
ular concern for patients undergoing bone marrow transplantation
(BMT) given the highly emetogenic agents used.
We conducted a retrospective observational study to verify the ef-
ficacy of our different prophylactic CINV prevention regimens for
different types of BMTperformed at our center.We looked at 78 au-
tologous and 38 allogeneic BMT patients hospitalised between au-
gust 2007 and july 2009. Patients received our standard antiemetic
prophylaxis tailored to the preparative regimen. Most patients re-
ceived a 5-HT3 antagonist and dexamethasone as prophylaxis and
prochlorperazine for breakthrough nausea. We measured emesis,
nausea and use of breakthrough antiemetics on a daily basis. Results
of the overall absence of emesis, nausea and non-use of breakthrough
antiemetics throughout the entire duration of the BMT process are
given in the following table.
Table 1. Control of nausea and emesis by preparative regimen
BEAM HD-Mel Flu-Cy TBI-Cy Bu-Cy Flu-Bu-ATGAbsence of vomiting 59.6% 29.0% 38.5% 0% 33.3% 66.7%
Absence of nausea 25.5% 6.5% 15.4% 0% 0% 50%
Non-use of
breakthrough
agents25.5% 12.9% 15.4% 0% 0% 50%In the daily evaluations, patients receiving the BEAM regimen and
the high-dose melphalan (HD-Mel) were particularly at risk of eme-
sis immediately following the melphalan. Control of CINV was ap-
proximately 90%before administration ofmelphalan and dropped to
45% on the following days.
The study included only a small number of patients in the alloge-
neic BMT setting. This group was then divided in even smaller co-
horts for each different regimen making it harder to reach
conclusions. However, all groups showed a low incidence of com-
plete control of CINV. The use of high dose cyclophosphamide
has a preparative regimen is associated with very poor nausea con-
trol.
This retrospective case study demonstrates the need to reassess
periodically the effectiveness of our prophylactic regimens for
emesis in the BMT setting and to make the appropriate changes
to improve our supportive care. Our center has changed our pro-
phylactic CINV prevention regimens and aprepitant (Emend)
has been added to some of BMT regimens even if it has not yet
received approval for this indication. Ongoing trials are assessing
its efficacy but early trials have successfully proven its safety. A
second study is planned at our center to evaluate if these modifi-
cations will improve the control of nausea and emesis in our BMT
patients.356
BK VIRUS ASSOCIATED HEMORRHAGIC CYSTITIS IN PEDIATRIC PA-
TIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT
Shakhnovits, M.1, DiMundo, J.1, Pawlowska, A.1, Wolfson, J.1,
Qian, D.2, Sorrell, A.1, Hitt, D.1, Dagis, A.2, Cheng, J.3, Rosenthal, J.1
1City of Hope, Duarte, CA; 2City of Hope, Duarte, CA; 3Kaiser-Perma-
nente, Los Angeles, CA
Background:Hemorrhagic cystitis (HC) is a severe complication in
pediatric and adult patients (pts) undergoing allogeneic hematopoi-
etic stem cell transplantation (HCT).HC is characterized by urothe-
lial inflammation and painful hematuria which can be microscopic
(Grade I) or macroscopic with blood clots and urinary tract obstruc-
tion (grade II-IV). The incidence of HC in pediatricHCTpts ranges
from about 10% to 20 % and morbidity and mortality is as high as
75% depending on the severity of HC. The etiology of delayed onset
of HC (greater than 2 weeks from conditioning therapy) is multifac-
torial, including damage from conditioning therapy, irradiation,
graft-versus host disease (GVHD), steroids, and viral infection.
